CDK4/6 INHIBITOR
Clinical trials for CDK4/6 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new CDK4/6 INHIBITOR trials appear
Sign up with your email to follow new studies for CDK4/6 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Brand or generic? new study tests palbociclib options for breast cancer
Disease control OngoingThis study compares the effectiveness and safety of brand-name palbociclib (Ibrance) versus a generic version in 100 Iraqi women with advanced HR+/HER2- breast cancer. The goal is to see if the generic works just as well in delaying cancer progression. Participants receive either…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: Al-Mustansiriyah University • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Blood test may predict cancer drug side effects before they happen
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at 100 women with breast cancer who are taking a type of pill called a CDK4/6 inhibitor. The goal is to find genetic and blood markers that can tell doctors ahead of time who might have bad side effects or not get enough benefit from the drug. By analyzing DNA an…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated Jun 02, 2026 11:40 UTC